The following information has been provided by Genentech.
“Genentech recently launched a new website GenentechHemophilia.com, dedicated to supporting the Hemophilia community. Here you can watch videos, read articles and learn how Genentech is committed to advancing all aspects of life with hemophilia A. Genentech supports the Hemophilia community through a variety of ways including a web series called Challenge Accepted. This web series shares what it means to live with a bleeding disorder. You’ll also find a new video featuring Genentech’s commitment to safety and their robust process to monitor the safety of its medicines.
Genentech’s partnership with the hemophilia community began over 30 years ago*Â when we developed our first medicine to help people with hemophilia A. This partnership continues today through a lasting commitment to the hemophilia A community that goes far beyond providing medicines.
We’re committed to advancing all aspects of life with hemophilia A, starting with patient care. We strive to provide Treatment for All who need it, including underserved communities around the globe.
We Connect the Community through active engagements that help bring these individuals together to learn and grow.
We Support the Person through education, resources and tools designed to help individuals thrive throughout their treatment journey.
With your help, we will continue to deliver now what the community needs next. That is our commitment to you.
Learn more at GenentechHemophilia.com.”
*Genentech out licensed worldwide production and marketing of factor VIII.
English 
Español de Puerto Rico